Description
General description
The chimeric transcription factor TEL-AML1 (ETV6-RUNX1) is the result of the reciprocal translocation t(12;21)(p13;q22), the most common structural genomic alteration found in childhood B-cell precursor acute lymphoblastic leukaemia (ALL). The runt-homology DNA-binding domain of AML1 retained in the TEL-AML1 mediates the DNA-binding activity of the fusion protein. The fusion protein not only exhibits altered transcription activity, it also affects normal transcription activity by directly competing against wild-type AML1 for promoter binding, sequestering transcriptional cofactors available for the wild-type protein, as well as dimerizing with wild-type protein.
Immunogen
KLH-conjugated linear peptide corresponding to human TEL-AML1 fusion.
Application
Anti-TEL-AML1 fusion Antibody, clone 6F2 is an antibody against TEL-AML1 fusion for use in Western Blotting, Flow Cytometry, Chromatin Immunoprecipitation .
Flow Cytometry Analysis: A representative lot detected TEL-AML1 fusion induction upon mifepristone treatment in BA/F3 cells expressing inducible TEL-AML1 fusion (Linka, Y., et al. (2013). Blood Cancer J. 3:e151).
Chromatin Immunoprecipitation Analysis
Analysis Note
Evaluated by Western Blotting in lysate from mifepristone-treated murine BA/F3 cells expressing inducible TEL-AML1 fusion.
Western Blotting Analysis: A 1:20,000 dilution of this antibody detected TEL-AML1 fusion induction in 2.5 ug lysate from mifepristone-treated murine BA/F3 cells expressing inducible TEL-AML1 fusion.
Other Notes
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial
